In the Boardroom
Refine search
Biotechnology
US clinical stage biotech Callio Therapeutics has announced the appointment of Zachary (Zach) Hornby as chief executive (CEO). 10 September 2026
Pharmaceutical
US targeted cardiometabolic therapeutics company Sparrow Pharmaceuticals has announced the appointment of George Eldridge as chief financial officer (CFO). 9 September 2026
Pharmaceutical
New Jersey, USA-based precision oncology company PMV Pharmaceuticals today announced the appointment of Philip Herman as chief commercial officer (CCO). 9 September 2026
Biotechnology
UK biotech Cytospire Therapeutics, which is developing differentiated multispecific immune cell engager antibodies, today announces the appointment of Dr Sumeet Ambarkhane as chief medical officer (CMO). 8 September 2026
Biotechnology
Australian late-stage biotech Neurizon Therapeutics today announced the appointment of Dr Chris Bremer as chief executive (CEO), effective October1, 2026. 7 September 2026
Pharmaceutical
Symbiosis Pharmaceutical Services, a UK-based specialist aseptic fill-finish contract development and manufacturing organisation (CDMO) headquartered in Stirling, Scotland, has appointed Jos Vergeest as senior business development director. 7 September 2026
Pharmaceutical
Bend Bioscience has announced the appointments of Pavlos Pavlidis as president and Sandeep Patel as chief financial officer, strengthening the company’s executive leadership team as it continues to expand its capabilities, operations, and support for pharmaceutical innovators. 4 September 2026
Biotechnology
Priothera, a late-stage clinical biopharmaceutical company, has announced the appointment of Dr Nigel Clark, as chief business officer (CBO). 3 September 2026
Biotechnology
Italian biotech Resalis Therapeutics has appointed Diana Røpcke as chief medical officer (CMO). 3 September 2026
Biotechnology
Connecticut-based Invivyd, a biopharma focused on protection from serious viral infectious diseases, has appointed Marc Elia, current chairman of its board, as chief executive. 3 September 2026
Biotechnology
UK clinical-stage biotech Redx Pharma has appointed Dr Mei-Lun Wang as chief medical officer (CMO) on a permanent basis, further strengthening the company’s clinical leadership and gastroenterology expertise. 2 September 2026
Biotechnology
French biotech firm Inventiva has appointed Chris Benecchi as chief operating officer, completing its leadership team roughly one quarter before the trial result that will decide the company's direction. Topline data from the pivotal Phase III NATiV3 study of lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH) are expected in the final quarter of 2026. 2 September 2026
Biotechnology
Waltham, Massachusetts-based advanced therapy contract development and manufacturing organization (CDMO) and gene editing services provider ElevateBio has announced the appointment of Steven Falcone as chief operating officer (COO). 1 September 2026
Biotechnology
Beam Therapeutics, a Cambridge, Massachusetts-based biotech developing precision genetic medicines through base editing, announced Tuesday the appointment of Eric Foster as chief commercial officer (CCO). 1 September 2026
Biotechnology
Immunic, a late-stage biotech developing oral therapies for neurological diseases, has appointed Chitrang Davé as chief data and digital officer (CDDO). 1 September 2026
Biotechnology
Eascra Biotech, a nanomedicine start-up with a laboratory in Worcester, Massachusetts, USA, has appointed Dr Andrew Goodearl, as chief scientific officer (CSO). 27 August 2026
Pharmaceutical
Swiss pharma services major Lonza Group has appointed Samanta Cimitan as chief commercial officer (CCO), senior vice president and a member of its extended executive committee. 26 August 2026
Biotechnology
Switzerland-based Celonic Group today announced that Dr Samanta Cimitan, chief executive (CEO), will be leaving the company toward the end of 2026 to pursue a senior leadership opportunity with one of the world's leading life sciences global organization. 26 August 2026
Pharmaceutical
Netherlands-based Qiagen announced that Jonathan Pratt has been appointed chief executive (CEO), effective September 1, 2026. He brings to Qiagen more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare. 25 August 2026
Pharmaceutical
Japanese drugmaker Daiichi Sankyo has appointed Ken Keller to the newly created role of chief commercialization officer (CCO), responsible for accelerating further growth of the company’s oncology and specialty medicine business through a new globally integrated commercialization unit, effective April 1, 2027. 24 August 2026
Biotechnology
US clinical-stage biotech Kailera Therapeutics, which is focused on elevating the next era of obesity care, has announced the appointment of Kathleen Tregoning as chief corporate affairs officer. 30 June 2026
Biotechnology
Candel Therapeutics has appointed oncology commercial veteran Mark Sims as chief commercial officer, effective July 6, as the company prepares for the potential launch of its lead cancer immunotherapy, aglatimagene besadenovec (CAN-2409), for localized prostate cancer. 26 June 2026
Pharmaceutical
Japanese pharma Takeda has formally appointed Julie Kim as president and chief executive, completing an 18-month leadership transition at the country’s largest drugmaker. 25 June 2026
Pharmaceutical
Germany’s Merck, which operates its Healthcare business sector as EMD Serono in the USA and Canada, today announced that Miguel Fernández Alcalde has been appointed head of global commercial strategy. 25 June 2026
Pharmaceutical
Danish CNS specialist Lundbeck has appointed Tarek Samad as executive vice president and head of Research & Development (R&D) and will join the executive leadership Team (ELT) effective 1 September 2026. 24 June 2026
Pharmaceutical
French pharma major Sanofi today announced the appointment of Paulo Fontoura as executive vice president, global head of research & development pharma, effective September 1, 2026. 22 June 2026
Pharmaceutical
UK specialty pharmaceutical company Essential Pharma has named Becki Morison as chief executive officer, effective July 1, as it looks to expand its rare disease and established brands businesses. 19 June 2026
Pharmaceutical
US pharma giant Pfizer is looking for a new chief financial officer after Dave Denton decided to leave the company for a role outside pharma. 19 June 2026
Biotechnology
German neuroscience company HMNC Brain Health has appointed former Lundbeck executive Bjørn Grønning as chief medical officer as it prepares two depression programs for Phase III-readiness activities. 17 June 2026
Biotechnology
Moderna today announced changes to its operating model to support its short- and long-term business goals, with the news sending the US mRNA vaccines firm’s shares up 3.5% to $53.97 by mid-morning. 16 June 2026
Pharmaceutical
US biotech Conexeu Sciences has added three directors to its board and named co-founder David Bogart as chief commercial officer, as the newly listed company looks to put more commercial muscle behind its regenerative tissue platform. 16 June 2026
Biotechnology
New Jersey, USA-based biotech Reunion Neuroscience has appointed Dr Sahil Kirpekar as its new president, chief executive (CEO) and a member of the board of Ddirectors, effective immediately. 16 June 2026
Biotechnology
Sweden’s Hansa Biopharma announced today the appointment of Adam Cutler as chief financial officer (CFO) and a member of the executive committee, effective June 22, 2026. 15 June 2026
Pharmaceutical
Canada-based clinical-stage drug developer ZYUS Life Sciences Corporation yesterday announced a strategic realignment of its corporate structure and leadership to strengthen its focus on the Company's core clinical development priorities. 12 June 2026
Biotechnology
Spanish women’s health biotech company Oriva Therapeutics has appointed Agnès Arbat as chief executive, as it advances a pipeline of treatments for chronic gynecological diseases led by the Phase I endometriosis candidate ORV-362. 11 June 2026
Biotechnology
UK biotech PhoreMost today announced its lead program, PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers. 10 June 2026
Biotechnology
German biotech CatalYm has appointed Peter Garcia as chief financial officer, adding a seasoned life sciences finance executive as its lead asset, visugromab, moves through a broad mid- to late-stage clinical program. 10 June 2026
Biotechnology
Swedish rare diseases company Hansa Biopharma today announced that Fredrik Röök has been appointed as vice president business development effective August 17. 10 June 2026
Pharmaceutical
Australia’s clinical-stage radiopharma company today announced the appointment of Justyna Kelly as chief technology officer (CTO) and François Gaudet as chief scientific officer (CSO), expanding the company’s executive leadership team in the USA as it continues to scale its US capabilities, and advance its growing pipeline of innovative targeted alpha therapies. 8 June 2026
Biotechnology
US biotech Cocrystal Pharma has appointed James Sapirstein as its chief executive (CEO), effective immediately. 3 June 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze